HOME >> BIOLOGY >> NEWS
Renowned Breast Cancer Experts Present Latest Findings At UCSF Cancer Center Symposium

The latest discoveries related to breast cancer research, diagnosis and treatment will be presented by several of the nation's most highly esteemed breast cancer specialists at a day-long symposium at the University of California San Francisco, Thursday, April 30, from 9:00 a.m. to 5:15 p.m., at Cole Hall on the UCSF campus.

Researchers will present up-to-date results regarding new breast cancer diagnostic techniques; the genetics of breast cancer and what it means for prevention, diagnosis and treatment; and changing trends in breast cancer incidence and mortality, including the role of diet, hormones and environment. In addition, researchers and patient advocates will describe the increasingly important role that patient advocates are playing in developing research and treatment programs and in improving treatment outcomes for cancer patients.

The symposium is sponsored by the UCSF Cancer Center, directed by Frank McCormick, PhD, the David A. Wood Professor of Tumor Biology and Cancer Research. The goal of the UCSF Cancer Center is to become the first NCI-designated comprehensive cancer center in Northern California. UCSF expects to apply for the designation this year.

Speakers at the UCSF Cancer Center's day-long symposium include: Virginia Ernster, PhD, UCSF professor of epidemiology and biostatistics at UCSF, will provide an overview on the latest demographic trends in breast cancer incidence and mortality. Ernster also will discuss risk factors for breast cancer, including lifestyle, hormonal, and environmental factors; possible preventive strategies; and the pros and cons of mammography screening.

Ernster, who along with her colleagues has described an "epidemic of diagnosis" of a type of breast cancer called ductal carcinoma in situ, leads a large National Cancer Institute (NCI)-funded project to establish a computerized population-based mammography registry for San Francisco that will be linked to other
'"/>

Contact: Jeffrey Norris
jnorris@itsa.ucsf.edu
(415) 476-2557
University of California - San Francisco
21-Apr-1998


Page: 1 2 3 4 5 6

Related biology news :

1. Renowned yeast and human geneticist at UCSF receives major research honor
2. Renowned author, scientist and professor, John L. Casti, returns to IIASA
3. Renowned Prostate Cancer Experts Present Latest Findings At UCSF Cancer Center Symposium
4. Breast cancer patients failed by treatment with taxol and taxotere respond to abraxane
5. Breastfeeding decreases infant mortality
6. Breast cancer study suggests role for tissue in carcinogenesis
7. Breast self examination increases womens concerns but has no effect on mortality
8. Breast cancer follow-ups no longer guess-work thanks to new physics research
9. Final media advisory for the 4th European Breast Cancer Conference (EBCC-4)
10. The 4th European Breast Cancer Conference (EBCC4)
11. Breast cancer susceptibility genes play role in DNA repair

Post Your Comments:
(Date:5/21/2013)... 21, 2013 Royal Philips Electronics (NYSE: PHG, ... first portable ultrasound with Philips, industry leading Live 3D ... CX50 xMATRIX with available Live 3D TEE and ICE ... at the EuroPCR, official meeting for the European Association ... Since its launch in 2012, Philips CX50 xMATRIX has ...
(Date:5/21/2013)... the way genes function without changing the underlying ... blood of pregnant women during any trimester, potentially ... the weeks after giving birth, and an opportunity ... findings of the small study involving 52 pregnant ... Molecular Psychiatry . , "Postpartum depression can be ...
(Date:5/20/2013)... also commonly resistant to antimicrobial substances made by ... mBio , the online open-access journal of ... and host antimicrobials LL-37 and lysozyme, which help ... that patients with life-threatening multi-drug resistant infections are ... is a last-line drug for treating several kinds ...
Breaking Biology News(10 mins):Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
(Date:5/21/2013)... Raleigh, NC (PRWEB) May 21, 2013 ... and financial services company for clinical trials, announced ... Aggregate Spend Solutions, LLC. Clinverse’s ClinPay® FLS ... automated investigator payment process. SpendMD ™, ... only complete solution for tracking and reporting transfer ...
(Date:5/21/2013)... 21, 2013 Smarter Security, Inc., provider ... today announced that Genzyme, a Sanofi company and leading ... Detective® CL for a multi-use facility in the United ... other Genzyme buildings, this latest order underscores the satisfaction ... tailgate detection device improving doorway access control. ...
(Date:5/21/2013)... ALBANY, New York , May 21, 2013 /PRNewswire/ ... published by Transparency Market Research ( http://www.transparencymarketresearch.com ) "Biochip ... Science Research, IVD Tests) - U.S. Industry Analysis, Size, Share, ... USD 2.4 billion in 2011 and is expected to ... 2018, to reach an estimated value of USD 4.7 ...
(Date:5/21/2013)... May 21, 2013 As the ... strong push within the industry to deliver better ... Organizations and pharma companies often means turning big ... Microtablets, developed in collaboration with Sensidose AB and ... can bring products to market sooner. The partnership ...
Breaking Biology Technology:Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2
Cached News: